New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas
Author: Ali Syed Arbab
Publsiher: Academic Press
Total Pages: 202
Release: 2021-03-05
ISBN 10: 0128232765
ISBN 13: 9780128232767
Language: EN, FR, DE, ES & NL

New Targeting in The Reversal of Resistant Glioblastomas Book Review:

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies
Author: Ramasamy Paulmurugan,Tarik F. Massoud
Publsiher: Academic Press
Total Pages: 828
Release: 2021-06-25
ISBN 10: 0128215682
ISBN 13: 9780128215685
Language: EN, FR, DE, ES & NL

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies Book Review:

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
Author: Anonim
Publsiher: Academic Press
Total Pages: 388
Release: 2021-08-11
ISBN 10: 0128243007
ISBN 13: 9780128243008
Language: EN, FR, DE, ES & NL

Overcoming Drug Resistance in Gynecologic Cancers Book Review:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
Author: Luc Friboulet
Publsiher: Academic Press
Total Pages: 216
Release: 2021-01-18
ISBN 10: 0128217790
ISBN 13: 9780128217795
Language: EN, FR, DE, ES & NL

Therapeutic Strategies to Overcome ALK Resistance in Cancer Book Review:

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer  Molecular Mechanisms and Therapeutic Strategies
Author: Chi Hin Cho,Tao Hu
Publsiher: Academic Press
Total Pages: 240
Release: 2020-05-24
ISBN 10: 0128199385
ISBN 13: 9780128199381
Language: EN, FR, DE, ES & NL

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies Book Review:

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
Author: Andrew Freywald,Franco Vizeacoumar
Publsiher: Academic Press
Total Pages: 308
Release: 2020-12-04
ISBN 10: 0128213116
ISBN 13: 9780128213117
Language: EN, FR, DE, ES & NL

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance Book Review:

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Drug Efflux Pumps in Cancer Resistance Pathways From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways  From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy
Author: Anonim
Publsiher: Academic Press
Total Pages: 394
Release: 2019-11-07
ISBN 10: 0128141417
ISBN 13: 9780128141410
Language: EN, FR, DE, ES & NL

Drug Efflux Pumps in Cancer Resistance Pathways From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy Book Review:

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance in cancer and is associated with therapeutic failure. Cancer types discussed include breast, endocrine, hematologic, gastrointestinal, musculoskeletal, lung, skin and central nervous system cancers. The book is a valuable source for researchers and advanced students in cancer, biology, pharmacology, pharmaceutical sciences, biomaterials and medical/clinical sciences that are interested in accessing a comprehensive compendium on efflux pumps in mechanisms of cancer resistance. Offers comprehensive and detailed descriptions of the basic aspects of efflux pumps in a very schematic and didactic manner Describes the involvement of efflux pumps in cancer resistance in different cancer types Encompasses an updated overview on state-of-the-art approaches that capitalize on their inhibition to improve chemotherapy and overcome resistance

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance
Author: Chunfu Wu,Lihui Wang
Publsiher: Academic Press
Total Pages: 144
Release: 2021-06-26
ISBN 10: 012823685X
ISBN 13: 9780128236857
Language: EN, FR, DE, ES & NL

Epigenetic Regulation in Overcoming Chemoresistance Book Review:

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
Author: Anonim
Publsiher: Academic Press
Total Pages: 294
Release: 2022-01-26
ISBN 10: 0323905560
ISBN 13: 9780323905565
Language: EN, FR, DE, ES & NL

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy Book Review:

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

Novel Therapies in Head and Neck Cancer Beyond the Horizon

Novel Therapies in Head and Neck Cancer  Beyond the Horizon
Author: Maie A. St. John,No hee Park
Publsiher: Academic Press
Total Pages: 266
Release: 2020-06-29
ISBN 10: 0128209291
ISBN 13: 9780128209295
Language: EN, FR, DE, ES & NL

Novel Therapies in Head and Neck Cancer Beyond the Horizon Book Review:

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients. Covers new chemotherapy trials, specifically on HPV and non-HPV related cancer types Discusses the application of immunotherapy to treat rare types of head and neck cancer Presents updated information on targeted therapies, specifically focusing on skin cancer in the region

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
Author: Goli Samimi,Christina Annunziata
Publsiher: Academic Press
Total Pages: 188
Release: 2020-11-06
ISBN 10: 0128198419
ISBN 13: 9780128198414
Language: EN, FR, DE, ES & NL

Overcoming Ovarian Cancer Chemoresistance Book Review:

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

pH Interfering Agents as Chemosensitizers in Cancer Therapy

pH Interfering Agents as Chemosensitizers in Cancer Therapy
Author: Claudiu Supuran,Simone Carradori
Publsiher: Academic Press
Total Pages: 228
Release: 2020-09-15
ISBN 10: 0128209283
ISBN 13: 9780128209288
Language: EN, FR, DE, ES & NL

pH Interfering Agents as Chemosensitizers in Cancer Therapy Book Review:

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Avastin and Malignant Gliomas

Avastin and Malignant Gliomas
Author: Thomas C. Chen,Marc C. Chamberlain
Publsiher: Bentham Science Publishers
Total Pages: 195
Release: 2010-12-28
ISBN 10: 9781608051328
ISBN 13: 1608051323
Language: EN, FR, DE, ES & NL

Avastin and Malignant Gliomas Book Review:

"Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconcl"

Resistance to Targeted Therapies Against Adult Brain Cancers

Resistance to Targeted Therapies Against Adult Brain Cancers
Author: Amanda Tivnan
Publsiher: Springer
Total Pages: 260
Release: 2016-11-26
ISBN 10: 3319465058
ISBN 13: 9783319465050
Language: EN, FR, DE, ES & NL

Resistance to Targeted Therapies Against Adult Brain Cancers Book Review:

This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.

Synthetic Nucleic Acids as Inhibitors of Gene Expression

Synthetic Nucleic Acids as Inhibitors of Gene Expression
Author: Levon Michael Khachigian
Publsiher: CRC Press
Total Pages: 200
Release: 2004-11-29
ISBN 10: 1420037897
ISBN 13: 9781420037890
Language: EN, FR, DE, ES & NL

Synthetic Nucleic Acids as Inhibitors of Gene Expression Book Review:

In the post-genomic era we have, at our fingertips, an incredible array of genomic sequences from a multitude of complex organisms. There remains, however, the critical need to understand the precise roles individual genes play in complex biological milieu. Synthetic nucleic acids are at the cutting-edge of molecular strategies that target genes of interest in a specific, efficient and cost-effective manner. These tools are now being used as new and exciting gene-silencing agents in vitro, in a panoply of animal models, and as novel therapeutics in human disease. Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms, Applications, and Therapeutic Implications brings together timely, authoritative reviews by renowned international leaders in the fields of ribozymes, RNA interference, DNAzymes and oligonucleotide decoys, with emphasis on biochemistry and translational research. The chapters on ribozymes include discussions of ribozyme subtypes, structure-function aspects, and therapeutic applications. This is followed by a comprehensive discussion of DNAzymes, their various subtypes, kinetics and biochemistry, and applications in target validation. Finally, the mechanisms and multiple therapeutic applications of double-stranded oligonucleotide decoys are described. For readers ranging from graduate students to researchers seeking target validation for pharmaceuticals to clinicians seeking innovative cancer and cardiovascular therapies, no resource is more complete and up to date than Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms, Applications and Therapeutic Implications.

Immunotherapeutic Strategies for the Treatment of Glioma

Immunotherapeutic Strategies for the Treatment of Glioma
Author: Christopher Jackson,Michael Lim
Publsiher: Academic Press
Total Pages: 190
Release: 2021-09-10
ISBN 10: 0128197560
ISBN 13: 9780128197561
Language: EN, FR, DE, ES & NL

Immunotherapeutic Strategies for the Treatment of Glioma Book Review:

Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward. The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics. This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy Provides a foundation for considering novel and combination therapies moving forward

Glioblastoma State of the Art and Future Perspectives

Glioblastoma  State of the Art and Future Perspectives
Author: Ghazaleh Tabatabai ,Hiroaki Wakimoto
Publsiher: MDPI
Total Pages: 784
Release: 2020-12-10
ISBN 10: 3039282603
ISBN 13: 9783039282609
Language: EN, FR, DE, ES & NL

Glioblastoma State of the Art and Future Perspectives Book Review:

Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.

Radiobiology of Glioblastoma

Radiobiology of Glioblastoma
Author: Luigi Pirtoli,Giovanni Luca Gravina,Antonio Giordano
Publsiher: Springer
Total Pages: 305
Release: 2016-06-06
ISBN 10: 3319283057
ISBN 13: 9783319283050
Language: EN, FR, DE, ES & NL

Radiobiology of Glioblastoma Book Review:

This text properly considers the most recent and relevant advances in molecular RB of GB, taking into account the related topics of pathobiology, and underscores the most promising translational perspectives from the preclinical to the clinical domain. Section I (From Bedside to Bench) discusses conditions associated with RT resistance of GB and the consequent RB hints, technology improvements intended to overcome RT-resistance of GB, mathematical modeling of RB parameters from clinical studies, the present impact of molecular prognostic factors in therapy of GB, and RT tolerance of normal brain. Section II (Preclinical Research and Pathobiology Topics) presents the traditional and mechanistic/molecular approaches to RB of GB, genetic and epigenetic studies on GB, issues of cell-death pathways, stem-like cells, invasiveness, tumor microenvironment, hypoxia, mi-RNA manipulations, and nanoparticle technology. Section III (Translational Perspectives) presents RB issues related to molecular profiling and classification of GB as frames of reference for clinical studies, translational perspectives of gene therapy, evolving protocols based on pre-clinical data and large data-bases and ontologic models. Radiobiology of Glioblastoma: Recent Advances and Related Pathobiology will be of great value to pathologists, medical oncologists, radiation oncologists as well as basic researchers and clinical investigators.

Drug Resistance in Cancer Cells

Drug Resistance in Cancer Cells
Author: Kapil Mehta,Zahid H. Siddik
Publsiher: Springer Science & Business Media
Total Pages: 363
Release: 2009-06-12
ISBN 10: 9780387894454
ISBN 13: 0387894454
Language: EN, FR, DE, ES & NL

Drug Resistance in Cancer Cells Book Review:

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

AACR 2016 Abstracts 1 2696

AACR 2016  Abstracts 1 2696
Author: American Association for Cancer Research (AACR)
Publsiher: CTI Meeting Technology
Total Pages: 135
Release: 2016-03-28
ISBN 10: 1928374650XXX
ISBN 13: 9182736450XXX
Language: EN, FR, DE, ES & NL

AACR 2016 Abstracts 1 2696 Book Review:

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients. This book contains abstracts 1-2696 presented on April 17-18, 2016, at the AACR Annual Meeting.